The efficacy and safety of 21-gene assay (Oncotype DX) in neoadjuvant endocrine therapy for postmenopausal breast cancer, single-arm phase II study.
Phase 2
Recruiting
- Conditions
- Breast CancerHormone receptor positive breast cancer, Neoadjuvant endocrine therapy, Oncotype DXD001940
- Registration Number
- JPRN-jRCT1032230536
- Lead Sponsor
- Takei Hiroyuki
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- 26
Inclusion Criteria
1. Women with untreated invasive and hormone receptor positive and HER2 negative breast cancer
2. Postmenopausal state
3. Can be written informed consent
Exclusion Criteria
1. BRCA1/2 variant
2. Allergy of hormone therapy or contrast agent
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method